top of page
Home
Purpose
People
Pipeline
Press
Contact
Praetego
Mar 1, 2023
FUNDING AWARDS
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy
Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M
Press + Announcements
Praetego’s progress is routinely updated as we strive to enter clinical trials. Please check back frequently for news, announcements, and events.
Home
Purpose
People
Pipeline
Press
Contact
bottom of page